OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE PUMP
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Advisors
    • Board Of Directors
  • PIPELINE
    • KETAMINE PATCH
    • KETAMINE PUMP
    • KETAMINE IV
  • INVESTORS
  • NEWS
  • CONTACT

News

9/16/2022

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinso

 

Read More

9/7/2022

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX Ketamine Patch

 

Read More

7/13/2022

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

 

Read More

6/29/2022

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

 

Read More

5/25/2022

PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

 

Read More

5/5/2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

 

Read More

4/25/2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

 

Read More

4/12/2022

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

 

Read More

3/23/2022

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

 

Read More

2/16/2022

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

 

Read More

2/1/2022

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

 

Read More

1/12/2022

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

 

Read More

1/4/2022

PharmaTher Announces Publication of Research Data for KETABET™

 

Read More

12/21/2021

PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

 

Read More

12/20/2021

PHARMATHER ENTERS INTO PROCESS DEVELOPMENT AGREEMENT WITH LTS LOHMANN FOR KETAMINE MICRONEEDLE PATCH

 

Read More
Previous

    Archives

    September 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

    Categories

    All

    RSS Feed

Psychedelic Pharmaceuticals

COMPANY  /  RESEARCH  /  INVESTORS  /  NEWS  /  CONTACT
Publicly-traded on the OTCQB: PHRRF and CSE: PHRM
© COPYRIGHT 2022.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.